logo
Tech fluency on corporate boards: embedding AI and innovation into business strategy

Tech fluency on corporate boards: embedding AI and innovation into business strategy

Fast Company2 days ago

As AI and disruptive technology keep changing the business world at lightning speed, boards are under constant pressure to stay on top. Innovation is a key part of how companies grow and stay competitive—but many boards still aren't ready for what's coming, says Sonita Lontoh, independent board director of Nasdaq-listed Sunrun and NYSE-listed TrueBlue and advisor at Silicon Valley VC firm Sway Ventures
CLOSING THE FLUENCY GAP
While every company is at a different point of maturity in its AI and technology journey, Lontoh sees a few challenges that boards often face. One of the biggest is the lack of technology literacy on many corporate boards—especially outside the tech industry. 'Many boards either don't have any real technology knowledge or rely too much on a single 'tech expert' to translate it all,' she says.
That's not optimal. Just like board members are expected to be financially literate, directors should have some level of technology fluency even when they may not necessarily need to be experts, Lontoh says. Without it, boards may lean too heavily on management's opinions. That can make it hard to challenge decisions when necessary or spot strategic, paradigm-shifting opportunities.
EMBEDDING TECHNOLOGY INTO BUSINESS STRATEGY
Another issue is that often, technology and innovation aren't fully integrated into the company's business strategy for long-term value creation. Lontoh notes that in some organizations, these efforts are still treated as siloed initiatives owned primarily by IT or the technology department. As a result, boards can struggle to evaluate whether tech investments are truly moving the company forward when innovation isn't linked to larger business goals. 'Boards need a holistic view so they can understand whether technology decisions are aligned with big-picture objectives and tech initiatives are actually resulting in real business outcomes,' she says.
On top of structural issues, there's also the sheer pace of technological advancement. Lontoh points to AI as a good example. 'Things are moving at an exponential pace, and boards are trying to figure out how to have the right governance frameworks that let companies explore new AI tools while still being ethical and responsible,' she says. Striking the right balance between innovation and risk is tricky, especially when the technology itself seems to evolve on an almost weekly basis.
OUTSIDE PERSPECTIVES
Lontoh has some suggestions on how boards can up their tech knowledge and fluency. First, boards should get regular briefings not only with internal tech leaders, but also to hear from outside experts. 'I've seen boards get a lot of value from meeting with venture capitalists or founders who've built and scaled disruptive companies, for example,' she says. These kinds of conversations help directors break out of old paradigms and spot new possibilities.
Boards should also mix their continuing education efforts by attending not just governance conferences, but also technology conferences, to hear first-hand from the leaders at the forefront of these new innovations and get a pulse of what's going on in the market.
She also recommends that board members try out emerging technologies firsthand. 'Especially with GenAI, just using it can be really eye-opening, but surprisingly, many global directors have little or no experience with it.' This needs to change, she says. 'The more hands-on experience directors can get, the better they'll understand what these tools can actually do.'
STRUCTURING AGENDAS AROUND INNOVATION
Another important question is how boards should structure their committees to ensure they have the time and space to oversee technology and innovation risks and opportunities adequately. There's no one-size-fits-all answer, Lontoh says. It depends on the company's industry, growth stage, and specific challenges. 'If you're in a high-growth space, your needs will be very different from a company in a declining category, for instance,' she notes.
Some boards assign all technology and cybersecurity risk oversight to the audit committee, but that may not always make sense. Instead, Lontoh suggests boards periodically reassess whether their current committee structures, compositions, and risk oversight allocations are still 'fit for purpose' to provide effective oversight for their particular situation.
That includes looking at whether it might be appropriate for some companies to have a standing technology and innovation committee to provide the board with the appropriate structure to be able to look at technology and innovation holistically—encompassing not just risks, but also opportunities, talent, and other aspects of technology and innovation that will create long-term business value for the company.
SETTING THE RIGHT TONE AT THE TOP
Boards also have an important role to play in encouraging innovation across the organization, Lonton says. That starts with mindset. 'Boards should set the right mindset to encourage management to look at technology and innovation as a strategic imperative that can materially change the long-term value of the company,' Lontoh says, 'and not just as an operational initiative.' She encourages boards to ask business leaders tough questions: How are these technology investments improving customer experience? Are they helping us retain talent? Are they actually moving the needle on growth?
And last but not least, boards should also influence management to adopt a healthy culture of innovation. 'A healthy culture of innovation combines an element of trust, openness, agility, and accountability,' Lontoh says, 'It's important because to be successful in innovation is as much about culture as it is about technology.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

Yahoo

time18 minutes ago

  • Yahoo

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio

Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target

Yahoo

time18 minutes ago

  • Yahoo

Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target

In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00. The analyst based the rating on the company's strategic developments and promising pipeline. One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates. A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals. The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases. While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.

Morgan Stanley Maintains Hold Rating on Snowflake (SNOW), Keeps $200 PT
Morgan Stanley Maintains Hold Rating on Snowflake (SNOW), Keeps $200 PT

Yahoo

time18 minutes ago

  • Yahoo

Morgan Stanley Maintains Hold Rating on Snowflake (SNOW), Keeps $200 PT

Keith Weiss from Morgan Stanley maintained a Hold rating on Snowflake Inc. (NYSE:SNOW) on June 4, keeping the associated price target at $200.00. The analyst has an optimistic yet cautious outlook on the company. Weiss noted that its recent Investor Day showcased several key product innovations, particularly in AI integration across the company's offerings, which provides Snowflake Inc. (NYSE:SNOW) a strong foundation for future growth. A software engineer at work, surrounded by a wall of computer monitors connected to a 'Data Cloud' platform. However, the analyst also reasoned that the event failed to provide substantial financial updates, which led to uncertainty surrounding Snowflake Inc.'s (NYSE:SNOW) immediate financial trajectory. Weiss acknowledged that the company is continuously expanding its capabilities to handle unstructured, structured, and multi-modal data. Despite that, he opined that the stock may be priced high compared to its near-term growth prospects, which can be corroborated by its current valuation at 55 times the projected free cash flow for 2026. While Snowflake Inc. (NYSE:SNOW) has attractive long-term potential, Weiss justified the Hold rating by recommending that investors wait for a more favorable entry point before raising their investments. Snowflake Inc. (NYSE:SNOW) provides cloud data warehousing software. Its offerings include Data Cloud, and its platform supports a number of use cases, including data engineering, data warehousing, data sharing, data science, data application development, and more. While we acknowledge the potential of SNOW as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store